| Shant Kazazian Md Inc. | |
|
204 E Chevy Chase Dr Ste 2 Glendale CA 91205-3181 | |
| (818) 545-9090 | |
| (818) 545-9098 |
| Full Name | Shant Kazazian Md Inc. |
|---|---|
| Speciality | Internal Medicine |
| Location | 204 E Chevy Chase Dr Ste 2, Glendale, California |
| Authorized Official Name and Position | Shant Kazazian (CEO) |
| Authorized Official Contact | 3233040975 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Shant Kazazian Md Inc. 204 E Chevy Chase Dr Ste 2 Glendale CA 91205-3181 Ph: (818) 545-9090 | Shant Kazazian Md Inc. 204 E Chevy Chase Dr Ste 2 Glendale CA 91205-3181 Ph: (818) 545-9090 |
| NPI Number | 1528377694 |
|---|---|
| Provider Enumeration Date | 10/06/2010 |
| Last Update Date | 07/07/2013 |
| Medicare PECOS PAC ID | 0143415760 |
|---|---|
| Medicare Enrollment ID | O20101109000975 |
News Archive
The Environmental Protection Agency (EPA) today released an Action Plan on bisphenol A (BPA).
AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced that the Company has entered into a multi-year development agreement with a leading international medical device company.
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 7 that the available data adequately demonstrate that the potential benefits of Contrave® (naltrexone sustained release (SR)/bupropion SR) outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.
Mice exposed to low temperatures develop more blood vessels in their adipose tissue and metabolise body fat more quickly, according to a new study from Karolinska Institutet. Scientists now hope to learn how to control blood vessel development in humans in order to combat obesity and diabetes.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528377694 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | A94612 (California) | Primary |
| Provider Name | Shant Kazazian |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1982646741 PECOS PAC ID: 0941202675 Enrollment ID: I20070209000298 |
News Archive
The Environmental Protection Agency (EPA) today released an Action Plan on bisphenol A (BPA).
AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced that the Company has entered into a multi-year development agreement with a leading international medical device company.
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 7 that the available data adequately demonstrate that the potential benefits of Contrave® (naltrexone sustained release (SR)/bupropion SR) outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.
Mice exposed to low temperatures develop more blood vessels in their adipose tissue and metabolise body fat more quickly, according to a new study from Karolinska Institutet. Scientists now hope to learn how to control blood vessel development in humans in order to combat obesity and diabetes.
› Verified 8 days ago
News Archive
The Environmental Protection Agency (EPA) today released an Action Plan on bisphenol A (BPA).
AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced that the Company has entered into a multi-year development agreement with a leading international medical device company.
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 7 that the available data adequately demonstrate that the potential benefits of Contrave® (naltrexone sustained release (SR)/bupropion SR) outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.
Mice exposed to low temperatures develop more blood vessels in their adipose tissue and metabolise body fat more quickly, according to a new study from Karolinska Institutet. Scientists now hope to learn how to control blood vessel development in humans in order to combat obesity and diabetes.
› Verified 8 days ago
Silva Karchikian, M.d. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 410 Arden Ave, Suite 101, Glendale, CA 91203 Phone: 818-549-9305 Fax: 818-662-8812 | |
Glendale Premier Medical Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 222 W Eulalia St, #201, Glendale, CA 91204 Phone: 818-240-0601 Fax: 818-240-0687 | |
Glenoaks Urgent Care Medical Group, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1100 W Glenoaks Blvd, Glendale, CA 91202 Phone: 818-242-3333 Fax: 818-546-1056 | |
Rubin Manavi, Md, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 214 N Central Ave, Glendale, CA 91203 Phone: 818-241-0970 Fax: 818-638-0024 | |
Armen Nercessian Do Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1122 N Brand Blvd Ste 101, Glendale, CA 91202 Phone: 818-552-2011 Fax: 818-552-2012 | |
Synergy Observation Specialists Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1509 Wilson Ter, Glendale, CA 91206 Phone: 818-409-8000 | |
Andy Chen M.d. A,medical Corporation Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1101 N Pacific Ave Ste 104, Glendale, CA 91202 Phone: 818-552-5000 Fax: 818-552-2959 |